文献速递肺栓塞与肺血管病间质性肺疾病

结节病相关肺动脉高压的管理与长期结局

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2017-10-19

该研究基于法国肺动脉高压注册中心2004至2015年数据,分析126例重度结节病相关肺动脉高压患者。77%接受PAH靶向治疗,4个月后肺血管阻力显著下降但运动能力无改善;中位随访28个月,1、3、5年生存率分别为93%、74%、55%,预后仍差。

要点

  • PAH靶向治疗可改善重度S-APH短期肺血流动力学但未提升运动能力
  • 部分患者免疫抑制治疗可改善血流动力学
  • S-APH长期预后仍较差,5年生存率55%

核心结论

  • PAH靶向治疗改善重度S-APH短期肺血流动力学但未改变运动能力,整体预后仍差。

研究设计与样本

  • 回顾性队列研究,数据来自法国肺动脉高压注册中心2004至2015年新诊断重度S-APH患者,共126例。

主要发现

  • 97例(77%)接受PAH靶向治疗,33例在诊断时启动或升级免疫抑制治疗。
  • PAH靶向治疗4个月后肺血管阻力从9.7±4.4降至6.9±3.0 Wood单位(p<0.001),运动能力无显著改善。
  • 11例仅接受免疫抑制治疗者中4例血流动力学改善,其中2例有压迫性淋巴结。
  • 中位随访28个月,39例需升级PAH靶向治疗,9例接受肺移植,42例死亡。
  • 1、3、5年生存率分别为93%、74%、55%。

关键数值与推荐

  • 重度S-APH定义:mPAP>35 mmHg,或mPAP 25-35 mmHg且心脏指数<2.5 L·min-1·m-2。
  • 患者平均年龄57.5±11.6岁,74%为影像学IV期。

临床怎么用

  • 对重度S-APH可考虑PAH靶向治疗以改善短期血流动力学。
  • 部分患者可从免疫抑制治疗中获益,尤其存在压迫性淋巴结者。
  • 需认识S-APH长期预后差,应密切随访并评估升级治疗或移植。

局限性

  • 注册中心回顾性数据,非随机对照设计。
  • 仅接受免疫抑制治疗者样本量小(11例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary hypertension (S-APH) are limited.Clinical and haemodynamic data from newly diagnosed patients with severe S-APH (mean pulmonary artery pressure (mPAP) >35 mmHg or mPAP 25-35 mmHg with cardiac index <2.5 L·min-1·m-2) were collected from the French Pulmonary Hypertension Registry between 2004 and 2015.Data from 126 patients with severe S-APH were analysed (mean±sd age 57.5±11.6 years, 74% radiological stage IV). 97 patients (77%) received PAH-targeted therapy and immunosuppressive therapy was initiated or escalated in 33 patients at the time of pulmonary hypertension diagnosis. Four months after PAH-targeted therapy initiation, mean±sd pulmonary vascular resistance decreased from 9.7±4.4 to 6.9±3.0 Wood units (p<0.001), without significant improvement in exercise capacity. Among the 11 patients treated only with immunosuppressive therapy, a haemodynamic improvement was observed in four patients, including two with compressive lymph nodes. After a median follow-up of 28 months, 39 patients needed PAH-targeted therapy escalation, nine underwent lung transplantation and 42 had died. Survival at 1, 3 and 5 years was 93%, 74% and 55%, respectively.PAH-targeted therapy improved short-term pulmonary haemodynamics in severe S-APH without change in exercise capacity. Immunosuppressive therapy improved haemodynamics in selected patients. Pulmonary hypertension in sarcoidosis remains associated with a poor prognosis.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017. PMID: 29051269. doi:10.1183/13993003.00465-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。